KYNTRA BIO, INC. (KYNB) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
34/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseKYNB / S&P 11.36% / 15.20% |
LoseKYNB / S&P -37.14% / 15.00% |
LoseKYNB / S&P -10390.91% / 50.40% |
| 2026-Q10/3 |
LoseKYNB / S&P -22.78% / -4.33% |
LoseKYNB / S&P 6.35% / 11.30% |
LoseKYNB / S&P -1750.61% / 27.70% |
| 2025-Q40/3 |
LoseKYNB / S&P -28.33% / 2.65% |
LoseKYNB / S&P -78.26% / 9.00% |
LoseKYNB / S&P -1253.94% / 13.40% |
| 2025-Q31/3 |
WinKYNB / S&P 131.13% / 8.12% |
LoseKYNB / S&P -117.53% / 4.61% |
LoseKYNB / S&P -690.93% / 13.45% |
| 2025-Q20/3 |
LoseKYNB / S&P -31.61% / 10.94% |
LoseKYNB / S&P -200.41% / 4.83% |
LoseKYNB / S&P -91.91% / 10.63% |
| 2025-Q10/3 |
LoseKYNB / S&P -41.51% / -4.27% |
LoseKYNB / S&P -80.57% / 4.98% |
LoseKYNB / S&P 0.00% / 10.57% |
| 2024-Q42/3 |
WinKYNB / S&P 32.83% / 2.41% |
LoseKYNB / S&P -36.71% / 5.25% |
WinKYNB / S&P 34.13% / 6.15% |
| 2024-Q31/3 |
LoseKYNB / S&P -55.27% / 5.89% |
LoseKYNB / S&P -130.54% / 5.89% |
WinKYNB / S&P 194.46% / 6.11% |
| 2024-Q21/3 |
LoseKYNB / S&P -62.04% / 4.28% |
LoseKYNB / S&P -105.60% / 5.38% |
WinKYNB / S&P 60.00% / 5.12% |
| 2024-Q11/3 |
WinKYNB / S&P 165.24% / 10.56% |
LoseKYNB / S&P -68.98% / 5.71% |
LoseKYNB / S&P -25.30% / 5.59% |
| 2023-Q40/3 |
LoseKYNB / S&P 2.67% / 11.69% |
LoseKYNB / S&P -66.74% / 6.81% |
LoseKYNB / S&P -6.98% / 7.78% |
| 2023-Q31/3 |
LoseKYNB / S&P -68.04% / -3.27% |
WinKYNB / S&P 26.09% / 7.52% |
LoseKYNB / S&P -21.08% / -5.03% |
| 2023-Q21/3 |
LoseKYNB / S&P -85.53% / 8.74% |
LoseKYNB / S&P -50.38% / 9.50% |
WinKYNB / S&P 43.46% / -8.57% |
| 2023-Q12/3 |
WinKYNB / S&P 16.48% / 7.50% |
LoseKYNB / S&P -54.96% / 10.77% |
WinKYNB / S&P 7.89% / -15.69% |
| 2022-Q41/3 |
WinKYNB / S&P 23.14% / 7.56% |
LoseKYNB / S&P -40.19% / 11.88% |
LoseKYNB / S&P KYNB unavailable / -17.99% |
| 2022-Q31/3 |
WinKYNB / S&P 23.20% / -4.88% |
LoseKYNB / S&P -56.69% / 13.47% |
LoseKYNB / S&P KYNB unavailable / -1.41% |
| 2022-Q22/3 |
WinKYNB / S&P -12.15% / -16.10% |
WinKYNB / S&P 53.15% / 13.71% |
LoseKYNB / S&P KYNB unavailable / 11.04% |
| 2022-Q11/3 |
LoseKYNB / S&P -14.75% / -4.60% |
WinKYNB / S&P 35.39% / 15.97% |
LoseKYNB / S&P KYNB unavailable / 42.23% |
| 2021-Q42/3 |
WinKYNB / S&P 37.96% / 11.03% |
WinKYNB / S&P 33.46% / 15.00% |
LoseKYNB / S&P KYNB unavailable / 96.40% |
| 2021-Q31/3 |
LoseKYNB / S&P -61.62% / 0.58% |
WinKYNB / S&P 137.87% / 10.77% |
LoseKYNB / S&P KYNB unavailable / 69.42% |
| 2021-Q21/3 |
LoseKYNB / S&P -23.28% / 8.55% |
WinKYNB / S&P 58.46% / 6.58% |
LoseKYNB / S&P KYNB unavailable / 51.81% |
| 2021-Q10/3 |
LoseKYNB / S&P -6.42% / 6.17% |
LoseKYNB / S&P -25.97% / -1.06% |
LoseKYNB / S&P KYNB unavailable / 7.39% |
| 2020-Q40/3 |
LoseKYNB / S&P -9.80% / 12.15% |
LoseKYNB / S&P -31.28% / -3.72% |
LoseKYNB / S&P KYNB unavailable / -33.42% |
| 2020-Q30/3 |
LoseKYNB / S&P 1.46% / 8.93% |
LoseKYNB / S&P -66.55% / -2.04% |
LoseKYNB / S&P KYNB unavailable / -27.10% |
| 2020-Q20/3 |
LoseKYNB / S&P 16.63% / 20.54% |
LoseKYNB / S&P -69.24% / -0.46% |
LoseKYNB / S&P KYNB unavailable / -27.11% |
| 2020-Q12/3 |
WinKYNB / S&P -18.98% / -19.60% |
WinKYNB / S&P 25.48% / 3.47% |
LoseKYNB / S&P KYNB unavailable / -14.75% |
| 2019-Q42/3 |
WinKYNB / S&P 15.98% / 9.07% |
WinKYNB / S&P 20.48% / 5.36% |
LoseKYNB / S&P KYNB unavailable / 2.99% |
| 2019-Q31/3 |
LoseKYNB / S&P -18.15% / 1.70% |
WinKYNB / S&P 162.94% / 5.02% |
LoseKYNB / S&P KYNB unavailable / 0.21% |
| 2019-Q21/3 |
LoseKYNB / S&P -16.87% / 4.30% |
WinKYNB / S&P 139.54% / 6.64% |
LoseKYNB / S&P KYNB unavailable / 8.65% |
| 2019-Q12/3 |
WinKYNB / S&P 17.44% / 13.65% |
WinKYNB / S&P 53.51% / 8.12% |
LoseKYNB / S&P KYNB unavailable / 14.29% |
| 2018-Q41/3 |
LoseKYNB / S&P -23.82% / -13.52% |
WinKYNB / S&P 62.57% / 9.05% |
LoseKYNB / S&P KYNB unavailable / 18.23% |
| 2018-Q30/3 |
LoseKYNB / S&P -2.96% / 7.71% |
LoseKYNB / S&P -0.11% / 10.21% |
LoseKYNB / S&P KYNB unavailable / 19.06% |
| 2018-Q22/3 |
WinKYNB / S&P 35.50% / 3.43% |
WinKYNB / S&P 17.41% / 9.03% |
LoseKYNB / S&P KYNB unavailable / 14.46% |
| 2018-Q10/3 |
LoseKYNB / S&P -2.53% / -0.76% |
LoseKYNB / S&P -27.59% / 7.68% |
LoseKYNB / S&P KYNB unavailable / 12.46% |
| 2017-Q40/3 |
LoseKYNB / S&P -11.90% / 6.64% |
LoseKYNB / S&P -28.49% / 7.03% |
LoseKYNB / S&P KYNB unavailable / 13.82% |
| 2017-Q31/3 |
WinKYNB / S&P 66.56% / 4.48% |
LoseKYNB / S&P -21.10% / 5.68% |
LoseKYNB / S&P KYNB unavailable / 17.57% |
| 2017-Q21/3 |
WinKYNB / S&P 31.03% / 3.09% |
LoseKYNB / S&P -22.41% / 4.83% |
LoseKYNB / S&P KYNB unavailable / 17.74% |
| 2017-Q11/3 |
WinKYNB / S&P 15.19% / 6.07% |
LoseKYNB / S&P -4.39% / 3.67% |
LoseKYNB / S&P KYNB unavailable / 13.32% |
| 2016-Q40/3 |
LoseKYNB / S&P 3.38% / 3.82% |
LoseKYNB / S&P 1.31% / 2.09% |
LoseKYNB / S&P KYNB unavailable / 7.05% |
| 2016-Q31/3 |
WinKYNB / S&P 26.14% / 3.85% |
LoseKYNB / S&P -0.22% / 0.20% |
LoseKYNB / S&P KYNB unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | KYNB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -32.38% | 20.78% |
| Annualized return | -32.38% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | KYNB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.42% | 83.14% |
| Annualized return | -51.87% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | KYNB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.15% | 319.30% |
| Annualized return | -32.91% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |